BeiGene, a global biotechnology company, announced the presentation of new data from its broad blood cancer portfolio of approved therapies and promising early-stage pipeline products at the 2023 European Hematology Association Hybrid Congress.
BeiGene, a global biotechnology company, announced the presentation of new data from its broad blood cancer portfolio of approved therapies and promising early-stage pipeline products at the 2023 European Hematology Association Hybrid Congress.